Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.

Probiotics Clinical Trial

Official title:

Evaluation of the Effects of Consumption of the Probiotic Strain Lactobacillus Coryniformis CECT5711 on the Immune Response to Influenza Vaccine in Adults Over 65 Years of Age.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03167593
• Other study ID #: P039
• Status: Completed
• Phase: Phase 2
• First received: May 23, 2017
• Last updated: May 24, 2017
• Start date: October 1, 2015
• Est. completion date: April 30, 2016

Study information

• Verified date: May 2017
• Source: Biosearch S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the present study is to evaluate the capability of the probiotic strain Lactobacillus coryniformis K8 CECT5711 (Lc K8) to enhance the immune response to influenza vaccine in elderly and the effect on respiratory symptoms related to respiratory infections.

A randomized, double-blind, placebo-controlled trial was conducted between November of 2015 and April of 2016. A total of 98 residents of nursing homes aged more than 65 years were randomly assigned to receive Lc K8 or placebo for two weeks previous to influenza vaccination.

Primary outcome was the percentage of seroconversion. Secondary outcome were the incidence of influenza-like illness and respiratory symptoms associated to respiratory infections during the follow-up period of 5 months. Serum cytokines and immunoglobulins levels were also evaluated.

Description:

The objective of the present study is to evaluate the capability of Lc K8 to enhance the immune response to influenza vaccine in elderly and the effect on respiratory symptoms related to respiratory infections.

A randomized, double-blinded, placebo controlled, multicenter trial was performed. The study was started on October 2015 and ended on April 2016. The recruitment of volunteers was carried out in five nursing home of Granada (Spain) at the beginning of the vaccination program.

Volunteers were randomly assigned to one of two groups. Those in the placebo group daily consumed a capsule containing 300 mg of maltodextrin. Those in the probiotic group daily consumed a capsule containing 3x10(9) colon-forming units of the strain Lc K8 in a matrix of maltodextrin.

From two weeks previous to the beginning of the intervention the consumption of any probiotic supplement was restricted until the end of the study. During two weeks before flu vaccination volunteers daily received a capsule of probiotic or placebo. Day 15 of the study all volunteers received intramuscular vaccination against flu (inactivated trivalent influenza: A/California/7/22009[H1N1]pdm09, A/HongKong/4801/2014[H3N2], B/Brisbane/60/2002) for the vaccine campaign of 2015/2016 (Sanofi Pasteur Europe, Lyon, France). All volunteers were vaccinated during the same week (second week of November 2015). After vaccination volunteer were followed-up until 31 of April 2016.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 98
• Est. completion date: April 30, 2016
• Est. primary completion date: January 7, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Residents in nursing home aged more than 65 years

Exclusion Criteria:

• Frequent gastrointestinal diseases, antibiotic treatment during the intervention, allergy to any groups of antibiotics, egg proteins or adjuvants and excipients of the flu vaccine

Related Conditions & MeSH terms

• Immune Response
• Influenza Vaccination
• Influenza, Human
• Probiotics

Intervention

Dietary Supplement:
• Lactobacillus coryniformis K8 CECT5711
Lactobacillus coryniformis CECT5711

Other:
• Control placebo
Maltodextrin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Biosearch S.A.

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cytokines	Interleukin-10, interleukin-4, tumor necrosis factor -alpha	3 months
Other	Immunoglobulins	Immunoglobulin A (IgA) and Immunoglobulin G (IgG)	3 months
Other	Gastrointestinal manifestations	Nausea, vomits and lack of appetite during follow-up period	5 months
Other	Medication	Consumption of analgesics and antibiotics during follow-up period	5 months
Primary	Percentage of seroconversion	According to the European Centre for Disease Prevention and Control (ECDC) for population older than 60 years old, seroconversion corresponds to the proportion of vaccinated individuals achieving a haemagglutination-inhibition (HAI) titre of >1:40 or a significant increase in HAI antibody titre, i.e. at least a four-fold titre increase.	2 months
Secondary	Incidence of influenza-like illness	Number of cases of influenza-like illness during the follow-up period (5 months)	5 months